Q1 2025 Charles River Laboratories International Inc Earnings Call Transcript
Key Points
- Charles River Laboratories International Inc (CRL) reported better-than-expected DSA performance, leading to a modest increase in financial guidance for the year.
- The company saw a return to a net book-to-bill ratio above 1 for the first time in over two years, indicating improved quarterly bookings.
- Operating margin increased by 60 basis points year-over-year, driven by cost savings from restructuring initiatives.
- Earnings per share rose by 3.1% from the first quarter of last year, supported by operating margin improvement and reductions in tax rate and interest expense.
- Charles River Laboratories International Inc (CRL) is actively investing in New Approach Methods (NAMs) and has a growing portfolio of capabilities in this area, positioning itself as a leader in preclinical drug development.
- Revenue for the first quarter of 2025 decreased by 2.7% compared to the previous year, with an organic decline of 1.8%.
- The company faces uncertainty due to government funding cuts, particularly at the NIH and FDA, and a slower start for biotech funding.
- RMS revenue declined by 2.5% on an organic basis, impacted by the timing of NHP shipments in China and lower revenue for the Cell Solutions business.
- The manufacturing segment's operating margin declined by 220 basis points due to lower commercial revenue in the CDMO business.
- The company is cautious about the second half of the year, with no assumption of a similar bookings tailwind benefiting revenue as seen in the first quarter.
Ladies and gentlemen, thank you for standing by, and welcome to the Charles River Laboratories first-quarter 2025 earnings conference call. This call is being recorded. (Operator Instructions)
I would now like to turn the conference over to our host, Todd Spencer, Vice President of Investor Relations. You may go ahead.
Good morning, and welcome to Charles River Laboratories' first-quarter 2025 earnings conference call and webcast. This morning, I am joined by Jim Foster, Chair, President and Chief Executive Officer; and Flavia Pease, Executive Vice President and Chief Financial Officer. They will comment on our results for the first quarter of 2025. Following the presentation, they will respond to questions.
There is a slide presentation associated with today's remarks, which will be posted on the Investor Relations section of our website at ir.criver.com. A replay of this call will be available beginning approximately two hours after the call
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
